Beone Medicines LTD. (BEIGF) — SEC Filings

Overview

Beone Medicines LTD. (BEIGF) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Nov 19, 2025: On November 13, 2025, BeOne Medicines Ltd. entered into a material definitive agreement, creating a direct financial obligation. The company, formerly known as BeiGene, Ltd. until August 19, 2015, is incorporated in Switzerland and its principal executive offices are located in Basel.

Sentiment Summary

Across 44 filings, the sentiment breakdown is: 4 bullish, 40 neutral. The dominant filing sentiment for Beone Medicines LTD. is neutral.

Filing Type Overview

Beone Medicines LTD. (BEIGF) has filed 26 8-K, 6 10-Q, 2 DEF 14A, 1 DEFA14A, 2 10-K/A, 2 10-K, 3 SC 13D/A, 2 SC 13G/A with the SEC between Jan 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (44)

• 8-K Filing — 8-K · Dec 19, 2025
• 8-K Filing — 8-K · Dec 18, 2025
• BeOne Medicines Ltd. Enters Material Definitive Agreement — 8-K · Nov 19, 2025 Risk: medium
  On November 13, 2025, BeOne Medicines Ltd. entered into a material definitive agreement, creating a direct financial obligation. The company, formerly known as
• BeOne Medicines Swings to Profit on Robust 41% Revenue Growth — 10-Q · Nov 6, 2025 Risk: medium
  BeOne Medicines Ltd. (BEIGF) reported a significant turnaround for the three and nine months ended September 30, 2025. Total revenues surged to $1,412,284 thous
• BeOne Medicines Ltd. Files 8-K on Financials — 8-K · Aug 29, 2025 Risk: low
  BeOne Medicines Ltd. filed an 8-K on August 29, 2025, reporting on its Results of Operations and Financial Condition, as well as Financial Statements and Exhibi
• BeOne Medicines Ltd. Enters Material Definitive Agreement — 8-K · Aug 25, 2025 Risk: medium
  BeOne Medicines Ltd. announced on August 25, 2025, that it entered into a material definitive agreement. This filing also indicates the creation of a direct fin
• BeOne Medicines Soars on Strong Q2 Product Sales, Collaboration Growth — 10-Q · Aug 6, 2025 Risk: medium
  BeOne Medicines Ltd. (BEIGF) reported a significant increase in product revenue for the three months ended June 30, 2025, reaching $456 million, up from $380 mi
• BeiGene, Ltd. Files 8-K on Security Holder Vote Matters — 8-K · May 21, 2025 Risk: low
  On May 21, 2025, BeiGene, Ltd. filed an 8-K report to announce the submission of matters to a vote of its security holders. The filing does not disclose specifi
• BeiGene Reports Unregistered Equity Sales — 8-K · May 13, 2025 Risk: medium
  On May 13, 2025, BeiGene, Ltd. filed an 8-K report detailing unregistered sales of equity securities. The filing indicates that the company has engaged in trans
• BeiGene, Ltd. Files Q1 2025 10-Q — 10-Q · May 7, 2025 Risk: medium
  BeiGene, Ltd. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates for the first quarter of 202
• BeiGene, Ltd. Files 8-K — 8-K · Apr 29, 2025 Risk: low
  BeiGene, Ltd. filed an 8-K on April 29, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not contain specific financial d
• BeiGene, Ltd. Files 8-K on Financials — 8-K · Apr 28, 2025 Risk: low
  BeiGene, Ltd. filed an 8-K on April 28, 2025, to report on its results of operations and financial condition. The filing includes financial statements and exhib
• BeiGene Files Definitive Proxy Statement — DEF 14A · Apr 7, 2025 Risk: low
  BeiGene, Ltd. filed its definitive proxy statement on April 7, 2025, for its annual meeting on May 21, 2025. The filing, designated as DEF 14A, outlines the com
• BeiGene Files Proxy Statement for Shareholder Meeting — DEFA14A · Mar 10, 2025 Risk: low
  BeiGene, Ltd. filed a Definitive Proxy Statement (DEFA14A) on March 10, 2025, for its Extraordinary General Meeting. The filing indicates that proxy materials a
• BeiGene Files 2024 Annual Report Amendment — 10-K/A · Feb 28, 2025 Risk: low
  BeiGene, Ltd. filed an amendment (10-K/A) to its annual report for the fiscal year ended December 31, 2024. This filing, submitted on February 28, 2025, serves
• BeiGene, Ltd. Files 2024 10-K — 10-K · Feb 27, 2025 Risk: medium
  BeiGene, Ltd. filed its 2024 10-K on February 27, 2025, detailing its operations for the fiscal year ending December 31, 2024. The company, operating in the pha
• BeiGene Files 8-K for Regulatory and Exhibit Disclosures — 8-K · Jan 13, 2025 Risk: low
  BeiGene, Ltd. filed an 8-K on January 13, 2025, to report information under Regulation FD and to file financial statements and exhibits. The filing does not con
• BeiGene Files 2023 Annual Report Amendment — 10-K/A · Jan 8, 2025 Risk: low
  BeiGene, Ltd. filed an amendment (10-K/A) to its 2023 annual report on January 8, 2025. The filing provides updated financial information for the fiscal year en
• BeiGene Files 8-K: Other Events & Exhibits — 8-K · Dec 23, 2024 Risk: low
  BeiGene, Ltd. filed an 8-K on December 23, 2024, reporting other events and financial statements/exhibits. The filing does not contain specific financial figure
• Baker Bros. Advisors Adjusts BeiGene Stake — SC 13D/A · Dec 10, 2024 Risk: medium
  Baker Bros. Advisors LP, through its affiliates FBB3 LLC and Baker Bros. Advisors (GP) LLC, has amended its Schedule 13D filing concerning BeiGene, Ltd. as of D
• BeiGene, Ltd. Files 8-K for Material Agreement — 8-K · Dec 10, 2024 Risk: medium
  On December 9, 2024, BeiGene, Ltd. entered into a material definitive agreement. This filing also indicates the creation of a direct financial obligation or an
• HHLR Advisors Ups BeiGene Stake to 10.4% — SC 13D/A · Dec 4, 2024 Risk: medium
  On December 4, 2024, HHLR Advisors, Ltd. filed an amendment (No. 5) to its Schedule 13D concerning BeiGene, Ltd. The filing indicates a change in beneficial own
• BeiGene, Ltd. Files 8-K — 8-K · Nov 19, 2024 Risk: low
  BeiGene, Ltd. filed an 8-K on November 19, 2024, reporting an event that occurred on November 14, 2024. The filing pertains to "Other Events" and "Financial Sta
• BeiGene, Ltd. Files 8-K with Financials and Exhibits — 8-K · Nov 14, 2024 Risk: low
  On November 14, 2024, BeiGene, Ltd. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating routine corporate disclosur
• BeiGene, Ltd. Files Q3 2024 10-Q — 10-Q · Nov 12, 2024 Risk: medium
  BeiGene, Ltd. filed its 10-Q for the period ending September 30, 2024. The company's fiscal year ends on December 31st. The filing includes financial data for t
• BeiGene, Ltd. Amends Schedule 13D/A for Leap Therapeutics — SC 13D/A · Oct 31, 2024 Risk: medium
  BeiGene, Ltd. has filed an amendment (Amendment No. 2) to its Schedule 13D/A regarding Leap Therapeutics, Inc. The filing, dated October 31, 2024, indicates a c
• BeiGene, Ltd. Files 8-K Report — 8-K · Oct 28, 2024 Risk: low
  On October 25, 2024, BeiGene, Ltd. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," with no specific f
• BeiGene, Ltd. Files 8-K on Sept 30, 2024 — 8-K · Sep 30, 2024 Risk: low
  BeiGene, Ltd. filed an 8-K on September 30, 2024, reporting other events and financial statements. The filing details the company's corporate information, inclu
• BeiGene Announces Board and Officer Changes — 8-K · Sep 26, 2024 Risk: low
  On September 25, 2024, BeiGene, Ltd. filed an 8-K report detailing changes in its board of directors and executive officers. The filing includes information reg
• BeiGene, Ltd. Files 8-K on Operations and Financials — 8-K · Aug 29, 2024 Risk: low
  On August 29, 2024, BeiGene, Ltd. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well as fin
• BeiGene, Ltd. Files 10-Q for Q2 2024 — 10-Q · Aug 7, 2024 Risk: medium
  BeiGene, Ltd. filed its 10-Q for the period ending June 30, 2024. The company, operating in the pharmaceutical preparations sector, reported financial results f
• BeiGene Announces Board Changes and Officer Compensation Details — 8-K · Jul 18, 2024 Risk: low
  On July 17, 2024, BeiGene, Ltd. announced changes to its Board of Directors, including the appointment of Dr. Xiaodong Wang as a Class II Director and the resig
• BeiGene Announces Executive Changes and Shareholder Votes — 8-K · Jun 5, 2024 Risk: medium
  On June 5, 2024, BeiGene, Ltd. filed an 8-K report detailing several key events. The company announced the departure of Director Robert J. H. Smith and the appo
• BeiGene, Ltd. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 8, 2024 Risk:
  BeiGene, Ltd. (BEIGF) filed a Quarterly Report (10-Q) with the SEC on May 8, 2024. BeiGene, Ltd. filed a 10-Q report for the quarterly period ended March 31, 20
• BeiGene, Ltd. Files Definitive Proxy Statement (DEF 14A) — DEF 14A · Apr 26, 2024 Risk: medium
  BeiGene, Ltd. (BEIGF) filed a Proxy Statement (DEF 14A) with the SEC on April 26, 2024. BeiGene, Ltd. filed a Definitive Proxy Statement (DEF 14A) on April 26,
• BeiGene, Ltd. Files 8-K on Financials — 8-K · Apr 26, 2024 Risk: low
  BeiGene, Ltd. filed an 8-K on April 26, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhib
• BeiGene, Ltd. Files 8-K with Financial Statements — 8-K · Apr 23, 2024 Risk: low
  On April 23, 2024, BeiGene, Ltd. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating it's an update or disclosure r
• BeiGene Appoints New CMO and CFO — 8-K · Mar 20, 2024 Risk: medium
  On March 19, 2024, BeiGene, Ltd. announced the appointment of Dr. Xiaojun Wang as Chief Medical Officer and Dr. Yong (Ben) Huang as Chief Financial Officer. The
• BeiGene, Ltd. Files 8-K Report — 8-K · Mar 15, 2024 Risk: low
  On March 14, 2024, BeiGene, Ltd. filed an 8-K report detailing "Other Events" and "Financial Statements and Exhibits." The filing does not contain specific fina
• BeiGene, Ltd. Files 8-K Report — 8-K · Mar 8, 2024 Risk: low
  On March 8, 2024, BeiGene, Ltd. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates or
• BeiGene, Ltd. Files 2023 Annual Report on Form 10-K — 10-K · Feb 26, 2024 Risk:
  BeiGene, Ltd. (BEIGF) filed a Annual Report (10-K) with the SEC on February 26, 2024. BeiGene, Ltd. filed its annual report for the fiscal year ended December 3
• Capital International Investors Holds 10.0% Stake in BeiGene — SC 13G/A · Feb 9, 2024 Risk: low
  Capital International Investors, a Delaware-organized entity, filed an amended SC 13G/A on February 9, 2024, disclosing its beneficial ownership in BeiGene, Ltd
• BeiGene CEO Oyler Holds 71.46M Shares, Signals Strong Insider Confidence — SC 13G/A · Feb 5, 2024
  John V. Oyler, CEO of BeiGene, Ltd., filed an amended SC 13G/A on February 5, 2024, disclosing his beneficial ownership of 71,464,808 ordinary shares as of Dece
• BeiGene 8-K Signals Officer/Director Changes, Comp Arrangements — 8-K · Jan 23, 2024
  BeiGene, Ltd. filed an 8-K on January 23, 2024, reporting an event that occurred on January 22, 2024. This filing indicates changes related to the 'Departure of

Risk Profile

Risk Assessment: Of BEIGF's 38 recent filings, 0 were flagged as high-risk, 16 as medium-risk, and 22 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Beone Medicines LTD.'s most recent 10-Q filing (Nov 6, 2025):

• Revenue: $1,412,284 thousand
• Net Income: $124,841 thousand
• EPS: $0.08
• Cash Position: $4,036,868 thousand
• Operating Margin: 11.55%

Key Executives

• Basel
• AESCHENGRABEN 27, 21ST FLOOR
• Felix J. Baker
• Julian C. Baker
• Dr. Xiaodong Wang
• Dr. Robert T. Li
• Robert J. H. Smith
• Dr. Xiaojun Wang
• Dr. Yong (Ben) Huang

Industry Context

The pharmaceutical industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. BeOne Medicines operates within this competitive landscape, where innovation and successful commercialization are key to growth. The sector is also subject to pricing pressures and patent expirations, making pipeline development and market access critical.

Top Tags

sec-filing (7) · financials (6) · pharmaceuticals (6) · financial-reporting (5) · 8-k (5) · amendment (5) · Pharmaceuticals (4) · 10-Q (4) · financial-obligation (3) · corporate-governance (3)

Key Numbers

• Total revenues (Q3 2025): $1,412,284 thousand — Increased 41.0% from $1,001,599 thousand in Q3 2024
• Net income (Q3 2025): $124,841 thousand — Swung from a net loss of $121,350 thousand in Q3 2024
• Total revenues (YTD Q3 2025): $3,844,863 thousand — Increased 43.3% from $2,682,417 thousand in YTD Q3 2024
• Net income (YTD Q3 2025): $220,431 thousand — Swung from a net loss of $492,905 thousand in YTD Q3 2024
• Cash and cash equivalents (Sept 30, 2025): $4,036,868 thousand — Increased from $2,627,410 thousand at Dec 31, 2024
• Proceeds from sale of future royalties (YTD Q3 2025): $885,000 thousand — Significant financing activity contributing to cash increase
• Research and development expenses (Q3 2025): $523,662 thousand — Increased 5.5% from $496,179 thousand in Q3 2024
• Selling, general and administrative expenses (Q3 2025): $528,998 thousand — Increased 16.2% from $455,223 thousand in Q3 2024
• Diluted EPS (Q3 2025): $0.08 — Improved from $(0.09) in Q3 2024
• Ordinary shares outstanding (Nov 1, 2025): 1,438,553,263 — Total shares outstanding
• Product Revenue for Q2 2025: $456M — Increased from $380M in Q2 2024, representing a 20% growth.
• Collaboration Revenue for Q2 2025: $120M — Increased from $95M in Q2 2024, showing strong partnership growth.
• Total Revenue for H1 2025: $1.1B — Increased from $950M in H1 2024, indicating robust half-year performance.
• Net Income for Q2 2025: $85M — A significant turnaround from a net loss of $15M in Q2 2024.
• Conformed Period of Report: 2025-06-30 — The end date for the financial period covered by this 10-Q filing.

Forward-Looking Statements

• {"claim":"Capital International Investors will maintain a significant stake in BeiGene, Ltd.","entity":"Capital International Investors","targetDate":"Next 12 months","confidence":"high"}

Related Companies

ONC · BGNE · LPTX

Frequently Asked Questions